|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta S, Kong W, Peng Y, Miao Q and
Mackillop WJ: Temporal trends in the incidence and survival of
cancers of the upper aerodigestive tract in Ontario and the United
States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pulte D and Brenner H: Changes in survival
in head and neck cancers in the late 20th and early 21st century: A
period analysis. Oncologist. 15:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fakhry C, Westra WH, Li S, Cmelak A, Ridge
JA, Pinto H, Forastiere A and Gillison ML: Improved survival of
patients with human papillomavirus-positive head and neck squamous
cell carcinoma in a prospective clinical trial. J Natl Cancer Inst.
100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zelefsky MJ, Harrison LB, Fass DE,
Armstrong JG, Shah JP and Strong EW: Postoperative radiation
therapy for squamous cell carcinomas of the oral cavity and
oropharynx: Impact of therapy on patients with positive surgical
margins. Int J Radiat Oncol Biol Phys. 25:17–21. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adelstein DJ, Li Y, Adams GL, Wagner H Jr,
Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup
phase III comparison of standard radiation therapy and two
schedules of concurrent chemoradiotherapy in patients with
unresectable squamous cell head and neck cancer. J Clin Oncol.
21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scanlan MJ, Simpson AJ and Old LJ: The
cancer/testis genes: Review, standardization, and commentary.
Cancer Immun. 4:12004.PubMed/NCBI
|
|
8
|
Sang M, Lian Y, Zhou X and Shan B: MAGE-A
family: Attractive targets for cancer immunotherapy. Vaccine.
29:8496–8500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: An expanding family of targets
for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atanackovic D, Altorki NK, Stockert E,
Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA,
Matsuo M, Selvakumar A, et al: Vaccine-induced CD4+ T cell
responses to MAGE-3 protein in lung cancer patients. J Immunol.
172:3289–3296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Müller-Richter UD, Dowejko A, Zhou W,
Reichert TE and Driemel O: Different expression of MAGE-A-antigens
in foetal and adult keratinocyte cell lines. Oral Oncol.
44:628–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sang M, Wang L, Ding C, Zhou X, Wang B,
Wang L, Lian Y and Shan B: Melanoma-associated antigen genes-an
update. Cancer Lett. 302:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krauss E, Rauthe S, Gattenlöhner S,
Reuther T, Kochel M, Kriegebaum U, Kübler AC and Müller-Richter UD:
MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig.
15:315–320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laban S, Giebel G, Klümper N, Schröck A,
Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R,
Gnjatic S, et al: MAGE expression in head and neck squamous cell
carcinoma primary tumors, lymph node metastases and respective
recurrences-implications for immunotherapy. Oncotarget.
8:14719–14735. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Laban S, Atanackovic D, Luetkens T, Knecht
R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A,
et al: Simultaneous cytoplasmic and nuclear protein expression of
melanoma antigen-A family and NY-ESO-1 cancer-testis antigens
represents an independent marker for poor survival in head and neck
cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cuffel C, Rivals JP, Zaugg Y, Salvi S,
Seelentag W, Speiser DE, Liénard D, Monnier P, Romero P, Bron L and
Rimoldi D: Pattern and clinical significance of cancer-testis gene
expression in head and neck squamous cell carcinoma. Int J Cancer.
128:2625–2634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hartmann S, Meyer TJ, Brands RC, Haubitz
IR, Linz C, Seher A, Kübler AC and Müller-Richter UD: MAGE-A
expression clusters and antineoplastic treatment in head and neck
cancer. Int J Mol Med. 35:1675–1682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hartmann S, Kriegebaum U, Küchler N,
Brands RC, Linz C, Kübler AC and Müller-Richter UD: Correlation of
MAGE-A tumor antigens and the efficacy of various chemotherapeutic
agents in head and neck carcinoma cells. Clin Oral Investig.
18:189–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hartmann S, Kriegebaum U, Küchler N,
Lessner G, Brands RC, Linz C, Schneider T, Kübler AC and
Müller-Richter UD: Efficacy of cetuximab and panitumumab in oral
squamous cell carcinoma cell lines: Prognostic value of MAGE-A
subgroups for treatment success. J Craniomaxillofac Surg.
41:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han L, Jiang B, Wu H, Zhang S and Lu X:
Expression and prognostic value of MAGE-A9 in laryngeal squamous
cell carcinoma. Int J Clin Exp Pathol. 7:6734–6742. 2014.PubMed/NCBI
|
|
21
|
Gu X, Fu M, Ge Z, Zhan F, Ding Y, Ni H,
Zhang W, Zhu Y, Tang X, Xiong L, et al: High expression of MAGE-A9
correlates with unfavorable survival in hepatocellular carcinoma.
Sci Rep. 4:66252014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatiboglu G, Pritsch M, Macher-Goeppinger
S, Zöller M, Huber J, Haferkamp A, Pahernik S, Wagener N and
Hohenfellner M: Prognostic value of melanoma-associated antigen A9
in renal cell carcinoma. Scand J Urol. 47:311–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu X, Tang X, Lu M, Tang Q, Zhang H, Zhu
H, Xu N, Zhang D, Xiong L, Mao Y and Zhu J: Overexpression of
MAGE-A9 predicts unfavorable outcome in breast cancer. Exp Mol
Pathol. 97:579–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu Y, Wang C, Zhang Y, Jia L and Huang J:
Overexpression of MAGE-A9 is predictive of poor prognosis in
epithelial ovarian cancer. Sci Rep. 5:121042015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhai X, Xu L, Zhang S, Zhu H, Mao G and
Huang J: High expression levels of MAGE-A9 are correlated with
unfavorable survival in lung adenocarcinoma. Oncotarget.
7:4871–4881. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhan W, Zhang Z, Zhang Y, Ma J, Wu T, Gu
Y, Li Y and Yang J: Prognostic value of MAGE-A9 expression in
patients with colorectal cancer. Clin Res Hepatol Gastroenterol.
40:239–245. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
28
|
Heo DS, Snyderman C, Gollin SM, Pan S,
Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whiteside
TL: Biology, cytogenetics, and sensitivity to immunological
effector cells of new head and neck squamous cell carcinoma lines.
Cancer Res. 49:5167–5175. 1989.PubMed/NCBI
|
|
29
|
Cooper JS, Pajak TF, Forastiere AA, Jacobs
J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al: Postoperative concurrent radiotherapy and chemotherapy for
high-risk squamous-cell carcinoma of the head and neck. N Engl J
Med. 350:1937–1944. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bernier J, Domenge C, Ozsahin M,
Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P,
Rolland F, Bolla M, et al: Postoperative irradiation with or
without concomitant chemotherapy for locally advanced head and neck
cancer. N Engl J Med. 350:1945–1952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Figueiredo DL, Mamede RC, Proto-Siqueira
R, Neder L, Silva WA Jr and Zago MA: Expression of cancer testis
antigens in head and neck squamous cell carcinomas. Head Neck.
28:614–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kerkar SP, Wang ZF, Lasota J, Park T,
Patel K, Groh E, Rosenberg SA and Miettinen MM: MAGE-A is more
highly expressed than NY-ESO-1 in a systematic immunohistochemical
analysis of 3668 cases. J Immunother. 39:181–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee KD, Lee HS, Kim SW, Park T, Hong JC,
Chang HK, Jung SB, Jeon CH and Park JW: Clinical significance of
melanoma-associated antigen A1-6 expression in sputum of patients
with squamous cell carcinoma of the larynx and hypopharynx. Head
Neck. 38 Suppl 1:E736–E740. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ries J, Agaimy A, Vairaktaris E, Kwon Y,
Neukam FW, Strassburg LH and Nkenke E: Evaluation of MAGE-A
expression and grade of dysplasia for predicting malignant
progression of oral leukoplakia. Int J Oncol. 41:1085–1093. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marcar L, Maclaine NJ, Hupp TR and Meek
DW: Mage-A cancer/testis antigens inhibit p53 function by blocking
its interaction with chromatin. Cancer Res. 70:10362–10370. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Monte M, Simonatto M, Peche LY, Bublik DR,
Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor
antigens target p53 transactivation function through histone
deacetylase recruitment and confer resistance to chemotherapeutic
agents. Proc Natl Acad Sci USA. 103:pp. 11160–11165. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang B, Oherrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et
al: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1
and suppress p53-dependent apoptosis in MAGE-positive cell lines.
Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hartmann S, Zwick L, Scheurer MJJ, Fuchs
AR, Brands RC, Seher A, Böhm H, Kübler AC and Müller-Richter UDA:
MAGE-A11 expression contributes to cisplatin resistance in head and
neck cancer. Clin Oral Investig. Oct 15–2017.(Epub ahead of print).
View Article : Google Scholar
|
|
39
|
Picard V, Bergeron A, Larue H and Fradet
Y: MAGE-A9 mRNA and protein expression in bladder cancer. Int J
Cancer. 120:2170–2177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wischnewski F, Pantel K and Schwarzenbach
H: Promoter demethylation and histone acetylation mediate gene
expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Mol Cancer Res. 4:339–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cacan E, Greer SF and Garnett-Benson C:
Radiation-induced modulation of immunogenic genes in tumor cells is
regulated by both histone deacetylases and DNA methyltransferases.
Int J Oncol. 47:2264–2275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yan Y, Hein AL, Etekpo A, Burchett KM, Lin
C, Enke CA, Batra SK, Cowan KH and Ouellette MM: Inhibition of RAC1
GTPase sensitizes pancreatic cancer cells to γ-irradiation.
Oncotarget. 5:10251–10270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Skvortsov S, Jimenez CR, Knol JC,
Eichberger P, Schiestl B, Debbage P, Skvortsova I and Lukas P:
Radioresistant head and neck squamous cell carcinoma cells:
Intracellular signaling, putative biomarkers for tumor recurrences
and possible therapeutic targets. Radiother Oncol. 101:177–182.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Skvortsov S, Dudás J, Eichberger P,
Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, Schartinger VH,
Maier H, Hall J, Debbage P, et al: Rac1 as a potential therapeutic
target for chemo-radioresistant head and neck squamous cell
carcinomas (HNSCC). Br J Cancer. 110:2677–2687. 2014. View Article : Google Scholar : PubMed/NCBI
|
